Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.53 |
| ▸ | ITGAV | P06756 | 2/20 | 0.53 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.53 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | SCN1A | P35498 | 1/20 | 0.51 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.51 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.51 |
| ▸ | DDX3X | O00571 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3347123 | 1.00 | RAB9A (0.56) | RAB9ANPC1HPGDALDH1A1POLB | |
| SCHEMBL3347133 | 1.00 | RAB9A (0.56) | RAB9ANPC1HPGDALDH1A1POLB | |
| SCHEMBL6351292 | 0.80 | NPC1 (0.62) | RAB9ANPC1HPGDALDH1A1POLB | |
| SCHEMBL3499028 | 0.79 | KMT2A (0.57) | RAB9ANPC1ALDH1A1LMNAGAA | |
| SCHEMBL7106954 | 0.79 | ALDH1A1 (0.58) | RAB9ANPC1HPGDALDH1A1POLB | |
| SCHEMBL19283574 | 0.79 | ALDH1A1 (0.58) | RAB9ANPC1HPGDALDH1A1POLB | |
| SCHEMBL15412316 | 0.79 | ALDH1A1 (0.58) | RAB9ANPC1HPGDALDH1A1POLB | |
| Cadaverine Tartrate SCHEMBL29071383 | 0.79 | TSHR (0.50) | RAB9ANPC1HPGDALDH1A1POLB | |
| Cadaverine Tartrate SCHEMBL28055271 | 0.79 | TSHR (0.50) | RAB9ANPC1HPGDALDH1A1POLB | |
| SCHEMBL19283507 | 0.79 | MAPT (0.57) | RAB9ANPC1ALDH1A1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156778-B2 | Cross-coupled peptide nucleic acids for detection of nucleic acids of pathogens | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-10-13 | — | — | US | disclosed |
| US-20120322053-A1 | CROSS-COUPLED PEPTIDE NUCLEIC ACIDS FOR DETECTION OF NUCLEIC ACIDS OF PATHOGENS | APPELLA DANIEL H (US) | 2012-12-20 | — | — | US | disclosed |
| US-20100120031-A1 | SYNTHESIS OF TRANS-TERT-BUTYL-2-AMINOCYCLOPENTYLCARBAMATE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF (US) | 2010-05-13 | — | — | US | disclosed |
| EP-0211584-A1 | Antihypertensive agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-02-25 | — | — | EP | disclosed |
| US-4618678-A | 4-(2,3-dichloro-6-fluorophenyl)-1,4,5,6,7,8-hexahydro-2-methyl-5-oxo-1,7-naphthyridine-3-carboxylic acid 2-(2,3-dichlorophenoxy)ethyl ester | AMERICAN HOME PRODUCTS CORPORATION (US) | 1986-10-21 | — | — | US | disclosed |
| US-4596873-A | 1,4,5,6,7,8-Hexahydro-2-alkyl-4-aryl-5-oxo-1,7-naphthyridine-3-carboxylic acid aromatic esters and pharmaceutically acceptable acid addition salts thereof useful as antihypertensive agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1986-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120031-A1 | SYNTHESIS OF TRANS-TERT-BUTYL-2-AMINOCYCLOPENTYLCARBAMATE | TERF2, TERF2IP, TCOF1 | RAB9A 2949/4885NPC1 2382/4885HPGD 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.